VITRAKVI (larotrectinib) oral solution. FDA Approved

FDA approved Anti-Cancer medicine VITRAKVI (larotrectinib) oral solution is available upon request. To get best retail price of VITRAKVI (larotrectinib) oral solution in India, For emergency product orders call 8750295029 (Mr. Neeraj Nagpal) or For enquires email info@medvitaz.com For advanced treatments in India, Medvitaz Pharma Solution can even help patient to discuss with oncologist.

VITRAKVI (larotrectinib) oral solution Initial U.S. Approval: 2018

INDICATIONS AND USAGE
VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:
• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
• are metastatic or where surgical resection is likely to result in severe morbidity, and
• have no satisfactory alternative treatments or that have progressed following treatment.
DOSAGE FORMS & STRENGTHS
• Capsules: 25 mg, 100 mg
• Oral Solution: 20 mg/mL
Manufactured By: HealthCare Pharmaceuticals Inc.
Prescribing Information URL: Click Here

HOW TO MAKE AN ENQUIRY FOR VITRAKVI (larotrectinib) oral solution?

FDA approved Anti-Cancer medicine VITRAKVI (larotrectinib) oral solution is available upon request. To get best retail price of VITRAKVI (larotrectinib) oral solution in India, For emergency product orders call 8750295029 (Mr. Neeraj Nagpal) or For enquires email info@medvitaz.com For advanced treatments in India, Medvitaz Pharma Solution can even help patient to discuss with oncologist.

Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.

Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion. Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.

Larotrectinib was approved for medical use in the European Union in September 2019. It was approved for medical use in Australia in August 2020.

HOW AND WHERE TO BUY larotrectinib oral solution?

You can order larotrectinib oral solution through Medvitaz Pharma Solutions under Named Patient Program (NPP). Medvitaz provides patients and physicians access to commercially approved medicines that are not available to them in their own country. Medvitaz objectives is to make quality medicines available at affordable prices for patients and physicians. To get best retail price/cost of larotrectinib oral solution in India, Call 8750295029 or Email urgent@medvitaz.com. FDA approved drugs of Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.